Pharma News

Advertisements of Alcohol during Live Sports Attract Children's to Alcohol

  • Posted on: 17 August 2015
  • By: Shalini.Sharma

A new Australian study has found that Advertisements of Alcohol during Live Sports Attract Children's to Alcohol than those who watch non-sport TV. The study was published in the journal PLOS ONE.

Restoring Testosterone in Older Men may Lower Risk of Heart Attack, Stroke, Death

  • Posted on: 15 August 2015
  • By: Shalini.Sharma

The study found Restoring testosterone in older men to normal level through gels, patches, or injections may lower their risk of heart attack, stroke, or death from any cause. The study appeared online in the European Heart Journal
Rajat Barua, assistant professor of medicine at the University of Kansas in the US, said, "It is the first study to demonstrate that significant benefit is observed only if the dose is adequate to normalize the total testosterone levels. Patients who failed to achieve the therapeutic range after testosterone replacement therapy did not see a reduction in (heart attack) or stroke and had significantly less benefit on mortality."

New Nasal Spray Flu Vaccine introduce for kids under Two, Adults above 49

  • Posted on: 15 August 2015
  • By: Shalini.Sharma

Currently nasal spray flu vaccine that uses a live but weakened form of the virus is not recommended for those under two as it is thought to be too strong to be safe for kids, and too weak to be effective for the elderly. Johns Hopkins researchers have developed a method to modify the nasal spray flu vaccine to make it effective for those under two and above 49 - two groups for which the vaccine is not approved. The study published online in the journal Vaccine.

Intrexon, Synthetic Biologics ink ECC introduce novel biotherapeutics to treat phenylketonuria

  • Posted on: 15 August 2015
  • By: Shalini.Sharma

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced an exclusive channel collaboration (ECC) to pursue the development and commercialisation of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.

Novartis Healthcare launches Sequadra inhaler for COPD treatment

  • Posted on: 14 August 2015
  • By: PharmaTutor News

Novartis Healthcare Private Ltd (NHPL) has launched Sequadra iInhaler  (indacaterol/glycopyrronium) 110mcg/50mcg, a fixed dose combination (FDC) of two bronchodilating active ingredients, indacaterol maleate, a long-acting beta2-adrenergic agonist (LABA) and glycopyrronium bromide, a long-acting anticholinergic (LAMA), for the treatment of chronic obstructive pulmonary disease (COPD).

Health Canada approves BTG's Varithena for varicose veins treatment

  • Posted on: 14 August 2015
  • By: PharmaTutor News

BTG plc, an international specialist healthcare company bringing announces that Health Canada has issued a Notice of Compliance approving Varithena (polidocanol injectable foam) for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system, above and below the knee.

Anticholinergic drugs may retard recovery of brain injury patients

  • Posted on: 14 August 2015
  • By: PharmaTutor News

New study has revealed that this group of drugs could delay the recovery of brain injury patients. Anticholinergic drugs help to block involuntary movements of the muscles. They are often used to treat a broad range of common conditions including bladder problems, insomnia and depression. The study was published in Brain Injury.

Pages